BIAF · bioAffinity Technologies filed a 424B5 prospectus supplement to…

bioAffinity Technologies filed a 424B5 prospectus supplement to increase the aggregate amount of common stock it may sell under its existing at-the-market (ATM) sales agreement with WallachBeth Capital by up to $3,428,226, bringing the total ATM capacity to $5,228,226. The company has already sold 114,672 shares for approximately $1.3 million under the agreement. This ATM increase adds further potential dilution to a micro-cap stock with a $4 million market cap, a going concern opinion, and a history of persistent net losses.

• The company increased its ATM offering capacity by $3,428,226, for a total of up to $5,228,226 in common stock sales.
• 114,672 shares have already been sold under the ATM agreement for gross proceeds of approximately $1.3 million.
• The last reported sale price on October 30, 2026 was $2.91 per share, down from the $15.27 reference price used for the non-affiliate market value calculation.
• The company has a going concern opinion from its auditor and persistent net losses ($14.9 million in 2025).